|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 48.34 USD | -4.28% |
|
-8.06% | +72.77% |
| 07-29 | Alkermes' Core Business Backed Q2 Beat, Orexin Pipeline to Serve as Catalyst, RBC Says | MT |
| 07-28 | Alkermes plc, Q2 2026 Earnings Call, Jul 28, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ALKERMES PLC | Other Biotechnology & Medical Research | -4.28% | -8.06% | +72.77% | +79.04% | +89.12% | 8.11B |  |  | |
- Stock Market
- Stocks
- ALKS Stock
- Charts Alkermes plc
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
